This website use cookies to ensure you get the best experience on our website
The global cannabis industry is poised for strong growth over the coming decade as legalization expansion accelerates across the world. Endless Biotech is at the forefront of transforming cannabis cultivation through its innovative approach to tissue culture technology. By harnessing the power of advanced biotechnology, our company is revolutionizing the way cannabis plants are propagated, cultivated, and preserved.
Tissue culture offers numerous advantages over traditional methods of plant propagation, including the ability to create genetically identical plants on a massive scale, free from pesticides, diseases, and genetic variations.
Cannabis consumers globally spent an estimated $415 billion on high-THC cannabis in 2020, with annual spending projected to climb to $496 billion by 2025.
Tissue culture is a method of growing new plants from tiny pieces of a plant, like a leaf or stem, in a special nutrient-rich gel. Think of it like planting seeds, but instead of seeds, we're using small plant parts. This allows us to grow many new plants that are exact copies of the original.
Why is Tissue Culture the Future of Cannabis?
• Healthier Plants: Tissue culture helps us grow plants that are free from diseases and pests, leading to healthier crops.
• Consistent Quality: Every plant grown from tissue culture is a clone, meaning they are all the same. This ensures consistent quality and potency in cannabis products.
• Faster Growth: Plants grown from tissue culture can grow faster and stronger, leading to quicker harvests.
• Space-Saving: We can grow many plants in a small space using tissue culture, making it more efficient and cost-effective.
• Preserving Genetics: Tissue culture allows us to preserve the genetic makeup of a plant, ensuring that rare or valuable strains are not lost.
Why not just use seeds? When you grow plants from seeds, each seed can produce a plant that's a bit different from the others. This means the plants can vary in size, strength, and quality. With tissue culture, we avoid this inconsistency because all the plants are an exact clone, giving us uniform and predictable results.
In short, tissue culture helps us grow better, healthier, and more consistent cannabis plants, making it a promising method for the future of cannabis cultivation.
In approximately 120 days, we can go from a single tissue culture plant to over seven million identical plants, guaranteed to be disease and pest free all grown in our sterile environment. This incredible speed and scale combined with our cutting edge technique with an expanded facility is how Endless Biotech will be changing the landscape of cannabis horticulture. This unimaginable scalability positions Endless Biotech to generate tremendous revenues considering each tissue culture clone sells between an average of $8.00 to $10.00 per clone depending on the quantities ordered by indoor and outdoor grow operations.
Most recent estimates, approximately 219 million individuals across the globe are reported to engage in the consumption and use of cannabis.
By leveraging the power of data analytics and scientific instrumentation, the Endless team is continuously pushing the boundaries of knowledge in cannabis cultivation, paving the way for achieving maximum success in producing premium quality pharmaceutical grade cannabis plants through tissue culture technology. Once final results are recorded the data is compiled and shared with our clients positioning them for the highest possibility of success.
INDUSTRY AVERAGE
THC: 15% - 25%
Terp Profile: 1.8% - 2.1%
Production of Flower: 55 grams/sqft
ENDLESS AVERAGE
THC: 28% - 34%
Terp Profile: 3.5% - 5.8%
Production of Flower: 115 - 120 grams/sqft
MEET THE ENDLESS BIOTECH TEAM
The Endless team is highly recognized for their science and biology background as well as their passion for revolutionizing the cannabis industry through cutting-edge tissue culture technology.
Our team includes top researchers, biotechnologists, PHD biochemist and a Nuclear Scientist leading the team who bring a wealth of knowledge and experience to the table. Each member has been carefully selected for their unique skills and contributions to advancing our mission of producing high-quality, genetically consistent cannabis plants at scale.
CHIEF EXECUTIVE OFFICER
International Finance
PRESIDENT, CHIEF OPERATING OFFICER
Nuclear Scientist & Engineer
CHIEF SCIENTIST
World Renowned Plant Scientist
CHIEF FINANCIAL OFFICER
Capital Markets
PLANT HEALTH & ANALYTICS
Bio-infomatics & Biologist
Endless has strategically partnered with leading industry innovators in the cannabis cultivation market.
Through collaborative efforts with our partners, Endless Biotech is actively engaged in targeting a global audience through collective strategic marketing initiatives. By aligning our marketing efforts with the expertise and reach of Fohse, Athena, Grodan, PIPP, and Quest, we aim to amplify our brand visibility and engage with potential customers on a global scale. Leveraging the established books of business of our partners, we can effectively tap into new markets, introduce our innovative solutions to a wider audience, and foster strong relationships with clients worldwide.
This synchronized approach to marketing not only enhances our market reach but also strengthens our position as a key player in the cannabis cultivation industry. By combining our resources, knowledge, and networks, we can create impactful marketing campaigns that resonate with diverse audiences, drive brand awareness, and ultimately support our mutual goal of expanding our global footprint and driving collective revenue growth.
A career spanning over two decades and experience in both national and international projects, with Braz on board, we are poised to meet our ambitious goal of producing 5,000,000 tissue culture clones per month. His expertise in tissue culture and plant biotechnology is exactly what we need to achieve this milestone and continue leading the industry in innovation and growth.
Endless is launching the 1st of 3 intended REG A+ $75 Million Capital Raises setting the stage for an anticipated 2027-2028 year end direct listing or Full S-1 Registration Initial Public Offering (IPO) onto the Nasdaq Stock Exchange.
A Licensed Medical Cannabis Operator who is now contracted to purchase & grow distribution of Endless's Tissue Culture Flower & Clones to dispensaries and grow operations.
This strategic partnership will grow the Endless Brand. In alliance, a strategic co-branding campaign of Conte TM Retail Packaged Flower will include "Powered by Endless" on all retail packaging.
The global cannabis market has experienced substantial growth, with estimates suggesting it has reached hundreds of billions of dollars annually. As nation continue to legalize the consumption and distributions of cannabis for both pharmaceutical and recreational use, demand for pharmaceutical grade genetics is exploding. The global cannabis market size is projected to grow from $57.18 billion in 2023 to $444.34 billion by 2030, at a CAGR of 34.03% during the forecast period. North America dominated the Global Market with a share of 81.79% in 2022.
Endless is currently working with grow operations across the world. Our pipeline of leads for both traditional clones and tissue culture could generate as much $120mm in annualized revenues. Endless is consistently receiving sales calls and leads from countries located across the globe desiring Endless's Tissue Culture & Clones
What truly sets Endless Biotech apart in the expanding global cannabis market is its ability to sell and distribute tissue cultures and clones to any grow operation worldwide. This is possible because Endless's tissue cultures and clones contain no THC at the point of sale, thanks to the plants' immaturity.
(Minimum 1,000 shares)
REG A+ "Regulation A" Stock Offering
HAVE QUESTIONS? CALL (918) 486-9451.
Thank you for getting in touch!
One of our colleagues will get back to you shortly.
Have a great day!